Exagen Appoints Wendy Johnson to Board of Directors
September 23 2020 - 04:10PM
Exagen Inc. (Nasdaq: XGN), an organization dedicated to
transforming the care continuum for patients suffering from
autoimmune diseases, is proud to announce the addition of Ms. Wendy
S. Johnson as an additional independent member to its Board of
Directors, effective October 1, 2020. Ms. Johnson will also serve
on the Audit Committee.
“We are excited to have added Ms. Wendy Johnson to our Board of
Directors,” said Ron Rocca, Exagen’s President and Chief Executive
Officer. “Her experience and knowledge in the healthcare industry
will be invaluable for the next phase of Exagen’s growth. Our
corporate culture of being patient-focused and discovery-driven
starts with our Board of Directors and extends out to every member
of Exagen. The announcement of Ms. Johnson joining our Board of
Directors underscores Exagen’s commitment to delivering on our
promise.”
Ms. Johnson has a distinguished career in healthcare performing
various roles integral to corporate growth. She is currently the
Chief Operating Officer of Reneo Pharmaceuticals where she is
responsible for day-to-day operations, and was instrumental in
setting up the company’s UK corporate entity. Ms. Johnson was
previously the Interim Chief Operating Officer of AmpliPhi
Biosciences Corporation from September 2014 to January 2017, and a
member of its board of directors from May 2014 until its merger
with C3J Therapeutics (Armata Pharmaceuticals) in May 2019. From
2005 to January 2014, Ms. Johnson served as a venture partner at
ProQuest Investments, a venture capital firm. From 2006 to January
2014, Ms. Johnson served as the President and Chief Executive
Officer of Aires Pharmaceuticals, a ProQuest portfolio company,
until its sale to MAST Therapeutics in 2014. Prior to joining
ProQuest, she held senior business and corporate development
positions at Salmedix Inc., WomenFirst Healthcare, Prizm
Pharmaceuticals (Selective Genetics Inc.), Cytel Corp., Synbiotics
Corp., and Murex Corp. (Cambridge U.K.). Additionally, Ms. Johnson
served as Assistant Director with the Center for Devices and
Radiological Health at the U.S. Food and Drug Administration. Ms.
Johnson is also presently on the Board of Directors of MorphoSys
AG, one of the oldest biotechnology companies in Europe. Ms.
Johnson received an M.B.A. from Loyola University Maryland, her
M.S. in Clinical Microbiology from the Hahnemann Medical School,
and her B.S. in Microbiology from the University of Maryland.
About Exagen
Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand, several of which are based on its proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable rheumatologists to improve care for
patients through the differential diagnosis, prognosis and
monitoring of complex autoimmune and autoimmune-related diseases,
including SLE and rheumatoid arthritis. Exagen’s model of
integrating testing products and therapeutics positions Exagen to
offer targeted solutions to rheumatologists and, ultimately, better
serve patients. For more information, please visit
www.Exagen.com.
CONTACTS:
InvestorsWestwicke PartnersMike
CavanaughMike.Cavanaugh@westwicke.com646.677.1838
Company ContactExagen Inc.Kamal Adawi, Chief
Financial OfficerKAdawi@exagen.com760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Mar 2023 to Mar 2024